dc.contributor.author |
Narender, Tadigoppula |
|
dc.contributor.author |
Madhur, Gaurav |
|
dc.contributor.author |
Jaiswal, Natasha |
|
dc.contributor.author |
Agrawal, Manali |
|
dc.contributor.author |
Maurya, C K |
|
dc.contributor.author |
Rahuja, Neha |
|
dc.contributor.author |
Srivastava, A K |
|
dc.contributor.author |
Tamrakar, A K |
|
dc.date.accessioned |
2013-07-16T11:02:39Z |
|
dc.date.available |
2013-07-16T11:02:39Z |
|
dc.date.issued |
2013 |
|
dc.identifier.citation |
European Journal of Medicinal Chemistry 2013, 63, 162–169 |
en |
dc.identifier.uri |
http://hdl.handle.net/123456789/1090 |
|
dc.description.abstract |
Abstract:
Diabetes mellitus is a metabolic disorder characterized by chronic hyperglycemia. α-Glucosidase (EC 3.2.1.20) inhibitors interfere with enzymatic action to slow down the liberation of D-glucose from oligosaccharides and disaccharides, resulting in delayed glucose absorption and decreased postprandial plasma glucose levels. In continuation of our drug discovery program on antidiabetic agents, we synthesized novel N-allylated/N-alkylated niacin and α-amyrin (4-9) and lupeol (12-16) hybrids and tested for their α-glucosidase inhibiting activity. Compounds 4-9 showed better activity profile than the marketed α-glucosidase inhibitor i.e. acarbose. Compound 4 possess the highest inhibitory action with IC50 of 5 µM. Kinetic and CD studies revealed that 4 inhibited the α-glucosidase in a noncompetitive manner and caused conformational changes in secondary structure of the enzyme protein |
en |
dc.format.extent |
825150 bytes |
|
dc.format.mimetype |
application/pdf |
|
dc.language.iso |
en |
en |
dc.relation.ispartofseries |
CDRI manuscript No 8397 |
en |
dc.subject |
α-Amyrin acetate |
en |
dc.subject |
Lupeol |
en |
dc.subject |
Niacin |
en |
dc.subject |
Triterpene-Niacin hybrids |
en |
dc.subject |
α-Glucosidase inhibitor |
en |
dc.title |
Synthesis of Novel Triterpene and N-Allylated/N-Alkylated Niacin Hybrids as α-Glucosidase Inhibitors |
en |
dc.type |
Article |
en |